Oral medication using Tolvaptan for ADL of patients with acute congestive heart failure

Oral medication using Tolvaptan for ADL of patients with acute congestive heart failure - Oral medication using Tolvaptan for ADL of patients with acute congestive heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013091

Enrollment

Registered

2014-02-07

Start date

2014-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

conventional intravenous treatment (without Tolvaptan) oral treatment including Tolvaptan (avoiding continuous intravenous therapy)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: agreement by patients beyond 20 years old diagnosed with acute congestive heart failure

Exclusion criteria

Exclusion criteria: acute myocardial infarction severe respiratory failure (PaO2<60Torr, and/or SPO2<90% on oxygen administration) shock vital (sBP<90mmHg) serum sodium >146

Design outcomes

Primary

Measure	Time frame
activity of daily living (ADL), quality of life (QOL)	—

Secondary

Measure	Time frame
Duration of hospitalization, place of discharge, cost	—

Countries

Japan

Contacts

Public ContactKazutaka Ueda

Tokyo Metropolitan Police Hospital Department of Cardiology

ueda-cib@umin.ac.jp+81-3-5343-5611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026